The experimental drug, a fixed-dose combination of an amylin receptor agonist and a GLP-1R/GIPR agonist, outperformed existing comparators in diet-induced obesity models. Researchers reported that the co-formulation achieved a 98% greater relative weight loss compared to eloralintide/tirzepatide and a 47% improvement over MET-233i/tirzepatide combinations. Beyond efficacy, the study highlighted the drug's physical stability, noting that it avoided the fibrotic aggregation issues frequently seen in similar peptide-based therapeutics under simulated storage conditions.

The pharmacokinetic profile appears to be the candidate's primary differentiator. In non-human primate models, the drug demonstrated half-lives of approximately 33 days for its amylin component and 30 days for its GLP-1R/GIPR component. This long-acting nature provides the foundation for the company’s push toward less frequent dosing schedules, which could significantly improve patient adherence compared to daily or weekly regimens. Ascletis has also confirmed the development of an oral tablet version of the formula, signaling a dual-track strategy for its weight-loss pipeline.